Accretion Pharmaceuticals's EBIT per Share for the
six
months ended in Mar. 2026 was ₹6.43.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹13.01.
During the past 12 months, the average EBIT per Share Growth Rate of Accretion Pharmaceuticals was 28.50% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 137.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Accretion Pharmaceuticals's EBIT per Share or its related term are showing as below:
NSE:ACCPL'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 137.3 Med: 137.45 Max: 137.6
Current: 137.3
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Accretion Pharmaceuticals was 137.60% per year. The lowest was 137.30% per year. And the median was 137.45% per year.
NSE:ACCPL's 3-Year EBIT Growth Rate is ranked better than 99.38% of 809
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs NSE:ACCPL: 137.30
Accretion Pharmaceuticals (NSE:ACCPL) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Accretion Pharmaceuticals EBIT per Share Related Terms
Accretion Pharmaceuticals EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹13.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Pharmaceuticals (NSE:ACCPL) has a EBIT per Share of ₹13.01 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Accretion Pharmaceuticals and its competitors. According to the industry distribution chart, Accretion Pharmaceuticals ranks #5 out of 809 companies in the Drug Manufacturers industry, placing it in the top 0.59999999999999%.
Is Accretion Pharmaceuticals' EBIT per Share too high?
Accretion Pharmaceuticals' current EBIT per Share is ₹13.01. Based on the distribution chart, Accretion Pharmaceuticals ranks #5 out of 809 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Accretion Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Pharmaceuticals' EBIT per Share compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Accretion Pharmaceuticals ranks #5 out of 809 companies for EBIT per Share. This places Accretion Pharmaceuticals in the top 1% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Accretion Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Pharmaceuticals's current EBIT per Share is ₹13.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Pharmaceuticals stock overvalued right now?
Accretion Pharmaceuticals (NSE:ACCPL) has a current EBIT per Share of ₹13.01. The current EBIT per Share is ₹13.01. Accretion Pharmaceuticals' overall GF Score™ is 30/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Accretion Pharmaceuticals (NSE:ACCPL), the current EBIT per Share is ₹13.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accretion Pharmaceuticals Ltd is engaged in the manufacturing of Medicinal & Pharmaceutical Products. The company manufactures tablets, oral liquid, capsule, cream, ointment, mouthwash, dusting powder, gel, ear drops, lotion, shampoo, powder, syrup, among others.
30GF Score
Get the complete analysis for NSE:ACCPL
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ACCPL has been successfully added to your 